GridAI Technologies Corp.
GridAI Technologies Corp.
- Market cap
- $32.44M
Your view on GRDX
Overview
What the company does, where it operates, and who runs it.
About GridAI Technologies Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason David Sawyer
- Headquarters
- GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason David Sawyer
- Headquarters
- GB
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide.
The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for GridAI Technologies Corp.. Starting points for GridAI Technologies Corp.: EPS -$1.94, beta 1.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for GridAI Technologies Corp.. Trailing twelve-month EPS for GridAI Technologies Corp. stands at -$1.94. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
1 rating- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$9,450.00 | −$10,080.00 | −$5.22 | −$4.95 |
| Lowest estimate | −$9,450.00 | −$10,080.00 | −$5.22 | −$4.95 |
| Highest estimate | −$9,450.00 | −$10,080.00 | −$5.22 | −$4.95 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | −$0.821 | −$4.16 | — |
| Growth vs a year ago | — | — | −25.5% | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $38110.00 | $38110.00 | $22.27M | $27.51M |
| Lowest estimate | $38110.00 | $38110.00 | $22.27M | $27.51M |
| Highest estimate | $38110.00 | $38110.00 | $22.27M | $27.51M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | $38208.00 | $36251.00 | — |
| Growth vs a year ago | — | −0.3% | +61319.0% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for GridAI Technologies Corp.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ALLRAllarity Therapeutics, Inc. | Healthcare | Biotechnology | $12.6M | ||
| ASBPAspire Biopharma Holdings, Inc. | Healthcare | Biotechnology | $822,602 | ||
| BCTXBriaCell Therapeutics Corp. | Healthcare | Biotechnology | $26.7M | ||
| CINGCingulate Inc. | Healthcare | Biotechnology | $67.5M | ||
| CRISCuris, Inc. | Healthcare | Biotechnology | $832,650 | ||
| CTXRCitius Pharmaceuticals, Inc. | Healthcare | Biotechnology | $14.0M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.4M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $8.8B | ||
| PDSBPDS Biotechnology Corporation | Healthcare | NASDAQ | $43.4M | ||
| PEPGPepGen Inc. | Healthcare | NASDAQ | $261.8M | ||
| PFNDPathfinder Cell Therapy, Inc. | Healthcare | OTC | $66,716 | ||
| PGENPrecigen, Inc. | Healthcare | NASDAQ | $1.5B | ||
| PHARPharming Group N.V. | Healthcare | NASDAQ | $814.5M | ||
| PHATPhathom Pharmaceuticals, Inc. | Healthcare | NASDAQ | $378.8M | ||
| PHGUFPharming Group N.V. | Healthcare | OTC | $1.1B | ||
| PHIOPhio Pharmaceuticals Corp. | Healthcare | NASDAQ | $7.8M | ||
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| DFSUDimensional - US Sustainability Core 1 ETF | $2.3B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in GRDX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold GridAI Technologies Corp., and how their positions are changing. At a $32.4M market value, institutional positions materially move GridAI Technologies Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by GridAI Technologies Corp. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for GridAI Technologies Corp.. Coverage tracks GridAI Technologies Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of GridAI Technologies Corp.